News for UroGen Pharma Ltd. (0XOD.L)

Market Analysis by covering: Nektar Therapeutics, UroGen Pharma Ltd, Verve Therapeutics Inc. Read 's Market Analysis on Investing.com

UroGen Pharma (URGN) is experiencing a notable rise in bullish option activity, with a total of 2,119 call options traded, exactly matching the expected volume.

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise

In the latest stock analyst update, Jason Kolbert from D. Boral Capital has maintained a "Buy" rating for UroGen Pharma (URGN). The current price target remain

UroGen Pharma (URGN) completes enrollment for Phase 3 UTOPIA trial of UGN-103 in bladder cancer treatment. The trial involves 99 patients across global

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (”œUroGen” or the

UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best hot stocks to buy according to Wall Street analysts. In mid-June, UroGen Pharma announced that the US FDA had approved ZUSDURI (mitomycin) for intravesical solution. This marked ZUSDURI as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI […]

PR NewswireNEW YORK, July 2, 2025 NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (”œUroGen” or the ”œCompan

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (”œUroGen” or the ”œCompan

PR NewswireNEW YORK, June 22, 2025 NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Lt

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (”œUroGen” or the ”œCompan

PR NewswireNEW YORK, June 17, 2025 NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Lt

PR NewswireLOS ANGELES, June 16, 2025 LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, remind

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday. Shares of Sage Therapeutics, Inc. SAGE rose sharply during Monday's sess...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Phar

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds UroGen Pharma Ltd. (”œUroGen”

UroGen Pharma (URGN) has been upgraded to a Buy rating from Neutral by H.C. Wainwright, with a price target set at $50. This change follows the announcement tha

U.S. stocks were lower, with the Dow Jones index falling around 600 points on Friday. Shares of Unusual Machines, Inc. UMAC rose sharply during Friday's sessio...